Quidel Corporation (NASDAQ: QDEL) recently received a number of ratings updates from brokerages and research firms:

  • 11/7/2017 – Quidel Corporation was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Quidel Corp. discovers, develops, manufactures and markets point-of-care, rapid diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions that affect women’s health throughout the phases of their lives including reproductive status, pregnancy management and osteoporosis. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, strep throat, H. pylori infection, chlamydia and infectious mononucleosis. “
  • 11/3/2017 – Quidel Corporation had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $50.00 price target on the stock.
  • 11/2/2017 – Quidel Corporation had its price target raised by analysts at Barclays PLC from $45.00 to $49.00. They now have an “overweight” rating on the stock.
  • 10/25/2017 – Quidel Corporation had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $48.00 price target on the stock.
  • 10/13/2017 – Quidel Corporation was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $50.00 price target on the stock. According to Zacks, “Quidel Corp. discovers, develops, manufactures and markets point-of-care, rapid diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions that affect women’s health throughout the phases of their lives including reproductive status, pregnancy management and osteoporosis. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, strep throat, H. pylori infection, chlamydia and infectious mononucleosis. “
  • 9/27/2017 – Quidel Corporation was upgraded by analysts at Zacks Investment Research from a “strong sell” rating to a “hold” rating. According to Zacks, “Quidel Corp. discovers, develops, manufactures and markets point-of-care, rapid diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions that affect women’s health throughout the phases of their lives including reproductive status, pregnancy management and osteoporosis. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, strep throat, H. pylori infection, chlamydia and infectious mononucleosis. “
  • 9/19/2017 – Quidel Corporation had its “buy” rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $47.00 price target on the stock, up previously from $41.00.
  • 9/19/2017 – Quidel Corporation was upgraded by analysts at Piper Jaffray Companies from a “neutral” rating to an “overweight” rating. They now have a $50.00 price target on the stock, up previously from $35.00.
  • 9/19/2017 – Quidel Corporation had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $48.00 price target on the stock, up previously from $42.00.
  • 9/19/2017 – Quidel Corporation had its “buy” rating reaffirmed by analysts at Barclays PLC. They now have a $45.00 price target on the stock, up previously from $39.00.

Shares of Quidel Corporation (NASDAQ:QDEL) opened at $38.18 on Tuesday. Quidel Corporation has a twelve month low of $18.25 and a twelve month high of $45.55. The company has a current ratio of 6.28, a quick ratio of 5.68 and a debt-to-equity ratio of 0.70.

Quidel Corporation (NASDAQ:QDEL) last issued its quarterly earnings data on Wednesday, November 1st. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.21). Quidel Corporation had a negative return on equity of 2.36% and a negative net margin of 2.33%. The company had revenue of $50.89 million for the quarter, compared to analyst estimates of $50.47 million. During the same quarter in the previous year, the business earned $0.10 earnings per share. The company’s revenue was up 3.1% on a year-over-year basis. equities analysts expect that Quidel Corporation will post 0.6 earnings per share for the current year.

In other Quidel Corporation news, SVP Werner Kroll sold 7,565 shares of Quidel Corporation stock in a transaction on Monday, November 6th. The shares were sold at an average price of $39.50, for a total value of $298,817.50. Following the sale, the senior vice president now directly owns 10,261 shares in the company, valued at approximately $405,309.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Ratan S. Borkar sold 7,965 shares of Quidel Corporation stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $38.91, for a total transaction of $309,918.15. Following the completion of the sale, the senior vice president now owns 11,084 shares in the company, valued at $431,278.44. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 135,530 shares of company stock worth $5,414,976. 22.00% of the stock is currently owned by company insiders.

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.

Receive News & Ratings for Quidel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel Corporation and related companies with MarketBeat.com's FREE daily email newsletter.